Story
Singapore Equities Top Asia in Q3; South Korean Tech Stocks See Sharp Pullback

Summary
Singapore's bank-heavy stock market surprisingly outperformed its Asian peers in the third quarter, while South Korea's tech-driven index saw a significant decline amid profit-taking and concerns over rising global bond yields.
Singapore's Straits Times Index (STI) emerged as Asia's top-performing stock market in the third quarter of 2026, a surprising development that saw its value-oriented, bank-heavy composition outperform the region's high-growth technology markets. In contrast, South Korea's KOSPI index was the region's biggest laggard, experiencing a sharp sell-off as investors took profits and weighed the impact of rising global interest rates.
A Quarter of Divergence
Market performance across Asia varied significantly during the three months ending September 30, according to data from Investing.com. The divergence highlights a potential shift in investor preference away from growth stocks, which are more sensitive to rising borrowing costs.
- Top Performer: Singapore's STI led the region with a gain of +10.42%.
- Biggest Laggard: South Korea's KOSPI plummeted -19.05%.
- Rebounding Markets: Jakarta's IDX Composite rose +8.70% and Hong Kong's Hang Seng gained +6.93%, both recovering from previously depressed levels.
- Other Decliners: China's Shanghai Composite fell -6.19%, while both Japan's Nikkei 225 and India's Nifty 50 shed -4.61%.
Profit-Taking Hits Tech, Value Stocks Gain
The sharp decline in South Korea's market appears to be driven by significant profit-taking. Despite the quarterly drop, the KOSPI remained up more than 62% year-to-date, following a more than 100% gain over the preceding 12 months. In contrast, Singapore's gains were described as steady and not merely a bounce from a low base.
AdThe artificial intelligence theme that has powered markets this year has not completely faded. The Taiwan Weighted index continued its ascent, rising +4.53% in the quarter and trading near its 52-week high. This suggests continued investor confidence in key players within the AI supply chain.
Rising Yields and Oil Prices Cloud Q4 Outlook
Looking ahead to the fourth quarter, the primary risks for Asian equities are macroeconomic. Soaring U.S. bond yields, which have reached two-decade highs, and elevated energy prices, with Brent crude near $105 a barrel, are creating significant headwinds. A stronger U.S. dollar, which gained about 2% in September, also typically pressures emerging market assets.
Analysts note that while strong corporate earnings have provided support for stocks so far, rising risk-free yields make it more difficult to defend high equity valuations. The key factor for the final quarter will likely be the trajectory of global bond yields, which could overshadow corporate earnings momentum and determine whether markets exposed to foreign capital and energy imports face further pressure.
Read next
More on Stocks
TDK, Taiyo Yuden Shares Climb on AI Component Partnership Talks
Shares of Japanese electronics makers TDK and Taiyo Yuden rose after the companies signed a memorandum of understanding to explore a business alliance for developing advanced components for the artificial intelligence industry.

Apple iPhone 18 Pro Sales Jump 12% in China Launch Week, Bucking Market Downturn
Sales of Apple's iPhone 18 Pro models rose 12% year-over-year during their first week in China, allowing the company to capture the top market position despite a significant slowdown in the country's overall smartphone market, according to Counterpoint Research.

Singapore Q4 Electricity Tariff to Fall 10.4% on Lower Energy Costs
Singapore's household electricity tariff will decrease by 10.4% for the fourth quarter, from October 1 to December 31, due to a drop in energy costs, according to provider SP Group. However, the company cautioned that recent increases in global fuel prices could lead to higher tariffs in the next quarter.

Bernstein Highlights Key China Biopharma Stocks for AI-Driven Drug Development
Bernstein has identified several Chinese biopharma companies, including WuXi AppTec and Hengrui Medicine, that are well-positioned to leverage AI. The firm's analysis favors companies with measurable R&D productivity and integrated platforms.